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Induced antigen-specific Foxp31 T cells (iTreg) are being discussed as a promising alter-
native to polyclonal natural Foxp31 T cells (nTreg) for cell-based therapies, particularly to
achieve transplantation tolerance. Using Foxp3eGFP-reporter mice, we here establish an
efficient protocol to induce and expand alloantigen-specific iTreg from Foxp3CD41 T cells
with cluster-disrupted DC. These iTreg were mainly CD62L1 and showed efficient
suppressive activity in vitro. However, in contrast to nTreg, adoptively transferred iTreg
entirely failed to prevent lethal graft versus host disease (GVHD). Within irradiated reci-
pients, the majority of adoptively transferred Foxp31 iTreg, but not Foxp31 nTreg quickly
reverted to Foxp3CD41 T cells. We therefore suggest that therapeutic approaches to treat
GVHD should rely on nTreg, whereas the use of de novo alloantigen-induced iTreg should
be handled with caution since the stability of the regulatory phenotype of the iTreg could
be of major concern.
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Introduction
Recent advances have demonstrated that adoptively transferred
exogenous Treg can inhibit graft versus host disease (GVHD)
[1–3]. However, the availability of sufficient numbers of donor
Treg for cell-based therapies remains limited [4]. Besides the in
vitro expansion of nTreg [5], an obvious approach to solve
this problem would be the de novo induction and expansion of
Foxp31 Treg from abundant naı¨ve CD41 T cells with recipient
alloantigens [6, 7]. Instead of mediating unspecific suppression,
such alloantigen-induced Treg potentially could provide the
advantage of antigen-specific regulation, thereby reducing the
risk of disease relapse and infections [8]. Here, we present an
efficient protocol to induce Foxp31 Treg by the use of cluster-
disrupted allogeneic DC. Such allo DC-induced iTreg were
functionally active in vitro and displayed a stable regulatory
phenotype upon adoptive transfer into untreated syngeneic
recipients. However, when used in experimental acute GVHD,
these cells quickly lost Foxp3 expression and, in contrast to
nTreg, did not show any protective effect.
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Results and discussion
To define conditions suited for the de novo induction of
alloantigen-specific iTreg, we isolated Foxp3CD41 T cells from
C57BL/6 Foxp3EGFP mice and co-cultured them with BM-derived
allogeneic BALB/c DC that were either matured by application of
LPS or via ‘‘cluster-disruption’’ (CD-DC). Disruption of the E-
cadherin-mediated cell–cell contacts induces DC maturation
through mechanisms distinct from TLR signaling [9]. Since
antigen-loaded CD-DC have been shown to induce tolerance in
mice after i.v. injection [9] we established a protocol that allowed
the conversion of naı¨ve to Foxp3 expressing cells in vitro in the
presence of allogeneic but not syngeneic CD-DC.
When compared with LPS-matured DC, CD-DC showed
equally high expression of MHC class II, but diminished upre-
gulation of the co-stimulatory molecules CD80, CD86 and CD40
(Fig. 1A). The co-culture of purified Foxp3CD41 T cells with
CD-DC under conditions supporting the generation of iTreg, i.e.
with TGF-b [10, 11], IL-2 [12] and retinoic acid (RA) [13, 14],
induced expression of Foxp3 in approximately 12% of CD41 T
cells (Fig. 1B). Intriguingly, the use of syngeneic DC did not lead
to iTreg-induction (data not shown), suggesting that the induced
Treg are specific for alloantigens. Along the same line LPS-
maturation of the allo CD-DC completely abolished their capacity
to induce Foxp3-expression on CD41 T cells under the same
culture conditions (Fig. 1B).
CD-DC-stimulated iTreg expressed CD25 as well as CD62L
(Fig. 1C) and were capable of suppressing in vitro the prolifera-
tion of CD41 and CD81 conventional T cells (Tconv) in a dose-
dependent manner with similar efficiency as directly sorted nTreg
(Fig. 1D). Of note, also CD251GFP T cells sorted from the
induction cultures exhibited some suppressive activity in vitro
(data not shown). This may be due the fact that some Foxp3
negative cells are also of a regulatory phenotype, such as
T regulatory 1 cells [15]. Next, we examined whether these
alloantigen-specific iTreg could interfere with the outcome of
GVHD as had been described for nTreg [1]. Lethally irradiated
(24 Gy) BALB/c recipients were transplanted with 5  106 T-
cell-depleted BM (TCD-BM) plus 5  105 MACS-purified Tconv
alone, or together with 5  105 FACS-sorted nTreg or iTreg.
Recipients of nTreg showed significantly improved survival and
morbidity compared with recipients of Tconv alone (Fig. 2A and
B). These data are in line with previous studies defining a
protective role for nTreg in GVHD [1, 16]. In marked contrast, we
did not observe any protective effect in mice receiving iTreg
(Fig. 2A and B). Therefore, the co-transfer of alloantigen-specific
iTreg was strikingly unsuccessful in inhibiting acute GVHD.
As nTreg were recently shown to proliferate in lymphopenic
hosts or after experimental HSCT in secondary lymphoid organs
(SLO) [17, 18], we determined the absolute numbers of trans-
ferred Foxp31 nTreg or iTreg at day 4 and day 8 after BM
transplantation (BMT) based on their GFP-expression. Notably,
we observed even higher numbers of GFP1 iTreg than GFP1
nTreg in spleen (SPL) and mesenteric lymph nodes (MLN) at both
time points (Fig. 2C). This may be a direct consequence of
continued iTreg expansion in vivo after alloantigen-specific acti-
vation in vitro. Moreover, the presence of both iTreg and nTreg in
SLO seemed to have similar negative effects on the priming and
proliferation of the transferred CD41 and CD81 effector T cells
(Fig. 2D). Still, dissimilar mechanisms may drive this apparent
inhibition of Tconv by iTreg or nTreg. In the case of iTreg, it could
be a combination of specific inhibition and competition for
specific antigen and other homeostatic survival factors.
We next investigated whether the failure of iTreg to protect
from experimental GVHD may be due to instability of their regu-
latory phenotype, i.e. loss of Foxp3 expression during further
activation and proliferation of the transferred iTreg in the condi-
tioned hosts. Therefore, the transferred Treg populations were
identified based on their congenic marker Thy1.1 and GFP
expression was assessed. Less than 15% of the iTreg had reverted in
vivo 8 and 14 days after transfer into untreated syngeneic mice
(Fig. 2E) confirming previously published results [14, 19]. In
contrast, Foxp3 expression of the transferred iTreg was not stable
after transfer to irradiated hosts (Fig. 2F). Even with499% pure,
double-sorted Foxp31 input cells, Foxp31 to Foxp3 reversion
rates were 70% after 4 days and 480% after 8 days for iTreg after
allogeneic transplantation (Fig. 2F). At the same time, reversion
rates of nTreg were only approximately 20% (Fig. 2F).
Complementary in vitro experiments showed that sorted pure
GFP1 iTreg but not nTreg were reconverted to a high degree into
GFP cells following allogeneic re-stimulation with CD-DC in the
absence of TGF-b and RA (Fig. 1E). Together, these in vivo and
in vitro findings suggest that allogeneic antigen-specific stimulation
in the absence of suppressive cytokines supported a rapid loss of
the previously induced Foxp3 expression. In vivo, these conditions
were granted through the inflammatory environment and severe
lymphopenia of the conditioned recipients. Likewise,
in vitro allogeneic activation in the absence of TGF-b-induced
similar rates of reversion to Foxp3 cells, highlighting the critical
importance of this cytokine in maintenance of the regulatory
phenotype [20]. In recipient mice, high reversion rates combined
with strong proliferation of the iTreg led to the accumulation of
Thy1.11, presumably alloantigen-specific effector T cells in the
recipients’ SLO (Fig. 2G). As a result, the ratio of Foxp31 to Foxp3
CD41 T cells may have turned unfavorable for the inhibition of
GVHD. Alternatively, the reverted former iTreg may themselves
have contributed as alloantigen-specific effector to the progression
of the disease. In vitro-induced iTreg showed a uniformly high
expression of GITR and of CD103 (Fig. 1C). Interestingly, expres-
sion of the adhesion molecule CD103 was rapidly lost after iTreg
transfer on both Thy1.11GFP1 as well as Thy1.11GFP cells. In
contrast, loss of GITR expression correlated with the loss of the GFP
reporter (data not shown). These observations further underline
the plasticity of induced Treg populations.
Concluding remarks
This is the first report addressing the efficacy of de novo-induced
alloantigen-specific Foxp31 Treg in experimental GVHD. Using
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allogeneic cluster-disrupted DC, we established a novel and
efficient protocol to generate inducible Foxp31 Treg.
In vitro, these cells display suppressive activity similar to
nTreg and when adoptively transferred to untreated syngeneic
recipients, keep Foxp3 stably expressed. However, adoptive
transfer of these cells has no beneficial effect in experimental
Figure 1. Allogeneic cluster-disrupted DC induce functional Foxp31 iTreg from Foxp3CD41 T cells. (A) Expression of MHC class II, CD80, CD86 and
CD40 on cluster-disrupted- (solid line), LPS- (dashed line), or immature– (dotted line) DC. Isotype controls are shown as gray lines. (B) MACS-
matured enriched CD41 T cells from Foxp3EGFP mice were FACS-sorted into GFP1 (to yield nTreg) and GFP fractions. GFPCD41 T cells were co-
cultured with cluster disrupted or LPS-matured DC. After 6 days, according to GFP expression, Foxp31 cells were re-sorted to a purity of 497% and
used as iTreg (the y-axis shows autofluorescence of the PE-channel, AF). (C) Expression of CD25, CD62L, CD103 and GITR of iTreg; isotype controls
are shown in gray. (D) iTreg and nTreg were cultured with CFSE-labeled Thy1.21 Tconv at the indicated ratios in the presence of anti-CD3/anti-CD28
beads. Proliferation of CD81 and CD41 Tconv are shown. (E) In vitro re-stimulation of sorted iTreg and nTreg in the presence of allogeneic CD-DC or
CD3/CD28 beads. Data are representative of at least three independent experiments.
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GVHD, although it has been shown that allo-antigen-expanded
Treg might be suitable to reduce allo-responses under non-
inflammatory conditions [21, 22]. In experimental GVHD, iTreg
are not stable and show only partial de-methylation of the Treg-
specific demethylated region within the Foxp3 locus (data not
shown), a phenomenon that seems to be common for in vitro
Figure 2. iTreg quickly revert in vivo and do not protect from lethal GVHD. (A) Survival and (B) weight loss of lethally irradiated BALB/c mice
receiving BMTwith allogeneic Tconv alone (w/o Treg) or together with iTreg, nTreg, or syngeneic grafts (syn. control) as indicated. Data are pooled
from two independent experiments. (C) Absolute cell counts of GFP1 iTreg and nTreg in mesenteric lymph nodes (MLN) and spleen (SPL) 4 and 8
days after transplantation (n5 7–9 mice/group from three independent experiments). (D) Four days after transplantation absolute cell numbers of
CD41 (left panel) and CD81 (right panel) Tconv from recipients’ MLN receiving either no Treg (w/o Treg), iTreg or nTreg (n5 7–9 mice/group from
three independent experiments). (E, F) Thy1.11GFP1 nTreg or Thy1.11GFP1 iTreg were adoptively transferred to Thy1.2 recipients. At the time
points indicated GFP expression was determined on Th1.11CD41 cells residing in the recipients’ MLN. (E) Non-irradiated syngeneic recipients at
day 8 and 14 after transfer. (F) Lethally irradiated BALB/c recipient receiving BMT plus Tconv together with iTreg or nTreg as indicated. (G) Same
experimental setup as described for (F). Absolute cell counts of donor-derived reconverted GFPCD41Thy1.11 donor cells isolated from recipients’
MLN and SPL. Data are representative of at least three independent experiments.
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generated iTreg [23]. Therefore, Foxp3-stability could be of
major concern regarding the therapeutic value of iTreg in the
lymphopenic environment after irradiation or chemotherapy.
However, this might not intrinsically be limited to iTreg since it
has recently been shown that nTreg can also turn into Th17
effector cells after transfer into lymphopenic hosts [24]. Along
the same lines, human nTreg have been reported to lose Foxp3
expression after repetitive TCR stimulation [25]. Intriguingly, we
find that approximately 80% of the transferred nTreg stably
remain Foxp31 even in the lymphopenic and inflammatory
environment of acute GVHD. Thus, the ensemble of factors
controlling stability or re-conversion of Treg under inflammatory
conditions has to better understood before these cells can broadly
applied in clinical settings.
Materials and methods
De novo induction of Foxp31 T cells
MACS-enriched (Miltenyi) CD41 T cells were sorted into GFP1
(nTreg) and GFP cells from C57BL/6 knock-in mice expressing
enhanced GFP under the control of an IRES element in the 30-
untranslated region of the Foxp3 gene (Foxp3EGFP) [26]. GFP
cells were then co-cultured for 6 days with either cluster
disrupted [9] (CD) or LPS-matured, BM-derived DC from
BALB/c mice (H-2d) in complete RPMI supplemented with
10 ng/mL rh-TGF-b (PeproTech), 5 nM retinoic acid (RA)
(Sigma) and 333 IU/mLl rh-IL2 (Roche). Afterwards, de novo-
induced Foxp31 cells (iTreg) were isolated in a second sort based
on GFP expression. Cell sorting was performed with a FACS Aria
(BD-Biosciences). T-cell stimulation was alloantigen-specific,
because we did not observe T-cell activation or iTreg induction
with syngenic C57BL/6 DC.
GVHD experiments
The C57BL/6 (H-2b) into BALB/c (H-2d) acute GVHD model was
performed as described elsewhere [1]. Recipients were moni-
tored for survival and weight loss. Where indicated, mice were
sacrificed and T-cell populations were analyzed using the
congenic marker Thy1.1 (Foxp3EGFP) and Thy1.2 (C57BL/6)
mice. All mice were bred at the central animal facility of
Hannover Medical School under specific pathogen-free condi-
tions. Donor and recipient mice were 6–10 weeks old. All animals
were handled in accordance with institutional and governmental
directives and were approved by local authorities.
In vitro suppression assay
Thy1.11 iTreg and nTreg were co-cultivated in round-bottom 96
well plates with MACS-enriched CFSE-labeled Thy1.21 T cells at
the indicated ratios under stimulatory conditions applying complete
RPMI supplemented with 100 IU/mL rh-IL2 and 15mL T-cell
expander beads (anti-CD3/anti-CD28, Dynal). After 4 days of
co-culture proliferation was assessed by flow cytometry determin-
ing CFSE dilution on live Thy1.21 T cells. Dead cells were identified
by counterstaining with 4’6-diamidino-2-phenylindol.
Data analysis and statistical analysis
FACS data were acquired on LSRII (BD-Biosciences) and
analyzed using FlowJo software. All fluorochrome-labeled anti-
bodies used in this study were obtained from BD-Bioscience.
Statistical data were analyzed using GraphPad-PRISM software.
Values are expressed as the mean7SD.
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